SynthesisPloS one2026
The effectiveness of smart healthcare for patients with rheumatoid arthritis: A systematic review and meta-analysis.
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the impact of smart healthcare interventions on disease activity, self-efficacy, self-management, functional levels, and quality of life in rheumatoid arthritis (RA) patients, as well as any associated adverse events.
methodA systematic search was conducted in PubMed, EMBASE, and Cochrane Library for randomized controlled trials (RCTs) from inception to August 2024, using relevant medical subject headings and keywords. The Cochrane risk of bias tool was employed to assess bias risk. A random effects model was used, calculating the standardized mean difference (SMD) and 95% confidence intervals (CIs). Heterogeneity was assessed with Chi-square and I2 tests.
resultThis meta-analysis included 18 RCTs published between 2015 and 2024, with follow-up periods ranging from 3 months to 1 year. Results revealed a significant reduction in Disease Activity Score 28 (DAS28) in the smart healthcare intervention group compared to controls [SMD 95% CI: -0.22 (-0.38, -0.05), I2 = 28.8%, P = 0.011]. Additionally, quality of life showed significant improvement as measured by EQ-5D scores [SMD 95% CI: 0.16 (0.01, 0.32), I2 = 0.0%, P = 0.033]. Significant improvement was also observed in functional capacity [SMD 95% CI: -0.30 (-0.54, -0.06), I2 = 0.0%, P = 0.014]. However, no statistically significant effects were found for self-efficacy [SMD 95% CI: 0.12 (-0.12, 0.35), I2 = 0.0%, P = 0.340], self-management ability [SMD 95% CI: 0.11 (-0.17, 0.39), I2 = 0.0%, P = 0.451], or RA knowledge [SMD 95% CI: 0.46 (-0.14, 1.07), I2 = 75.98%, P = 0.133].
conclusionSmart healthcare interventions show promise in reducing disease activity and improving physical function and quality of life in patients with rheumatoid arthritis. While these findings support the potential value of digital health solutions in RA management, further validation through more rigorous methodological designs is needed to confirm long-term effectiveness and clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.